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Human pepsinogen A3 and A5 have been purified to chromatographic and electrophoretic homogeneity. At pH 2 pep- 
sinogen A3 activates at a much faster ate than pepsinogen A5. Leu-23 - Lys-24 is the first bond cleaved uring activation 
of pepsinogen A3. This bond is also cleaved in pepsinogen A5, but together with the cleavage ofAsp-25 Phe-26. Amino 
acid sequencing shows that pepsinogen A3 has Glu at position 43, whereas pepsinogen A5 has Lys. 
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1. INTRODUCTION 
In the human gastric mucosa several 
isozymogens for pepsin A are found; these are 
numbered after their anodal  electrophoretic 
mobil it ies (reviews [1-3]). The heterogeneity arises 
both from genetic variations and from posttransla- 
t ional modif ications. The organization of 3 genes 
corresponding to PgA3, -4, and -5 has been map- 
ped [4,5]. Two of the genes have been investigated 
by nucleotide sequencing; a few differences were 
observed, e.g. Glu or Lys at posit ion 43 [6,7]. But 
the electrophoretic mobilities of the corresponding 
pepsinogens have not yet been published. 
The first step in the activation of the gastric 
zymogens consists of a conformat ional  change in 
which the active site is uncovered [8,9]. The reac- 
t ion proceeds by autocatalytic limited proteolyses 
which finally remove 42 to 47 amino acid residues 
from the N-terminal end of the zymogens, but in- 
termediates occur in which only 16 to 26 residues 
are cut off (reviews [2,3]). 
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In this communicat ion it is shown that the 
predominant  isozymogens PgA3 and PgA5 have 
different activation patterns, and the major  
cleavage site differs from that reported previously 
[10]. Furthermore, the known N-terminal se- 
quences are allocated to electrophoretically 
characterized isozymogens. 
2. MATERIALS  AND METHODS 
2.1. Pepsinogens 
Human gastric mucosa was obtained at autopsy from pa- 
tients without gastric disorders (Bispebjerg Hospital, 
Copenhagen). The pepsinogens were extracted and purified by 
chromatography on DEAE-cellulose as described previously 
[11]. The individual isozymogens were isolated from pools of 
the DEAE-chromatography by fast protein liquid 
chromatography (Mono Q, Pharmacia). Elution with a linear 
gradient from 0.05 M ammonium acetate, pH 5.6 to 0.5 M of 
the same buffer. PgA3 and PgA5 were eluted at buffer concen- 
trations of 0.33 M and 0.40 M, respectively. Pools of pure 
zymogens were dialyzed against 0.01 M sodium phosphate, pH 
7, before activation. 
2.2. Activation 
Temperature, 0°C; concentration f pepsinogen, 0.3 mg/ml; 
addition of 0.2 M HCI to pH 2. During the experiments, ali- 
quots were brought o pH 9 with 1 M ammonia, the samples 
were concentrated byfreeze-drying. 
2.3. Digestion with Armillaria mellea proteinase [12] 
Enzyme/substrate ratio 1 : 1000, digestion for 4 h in 0.2 M N- 
ethylmorpholine acetate, pH 8, at 37°C. 
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2.4. Electrophoreses 
Agar gel electrophoresis was carried out in 0.05 M sodium 
phosphate, pH 6.0, the zymograms were developed with 
haemoglobin [13]. SDS-PAGE was carried out with the 
Laemmli buffer system [14]: gel concentration, 15% T and 
0.5°7o C; length of separation gel, 15 cm. Coomassie brilliant 
blue G-250 was used for staining. 
2.5. Sequencing 
For sequence analyses, the polyacrylamide gel was elec- 
troblotted on a membrane of polyvinylidene difluoride (Im- 
mobilon Transfer, Millipore) [15]. Sequencing was carried out 
with a 477A Applied Biosystem analyzer equipped with on-line 
HPLC. 
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3. RESULTS AND DISCUSSION 
The isopepsinogens were purified to elec- 
trophoretic homogeneity as tested by agar gel elec- 
trophoresis at pH 6.0. The pattern of isozymogens 
was the same as that found previously at pH 8 [1], 
but the lower pH allows characterization of 
development of enzymic activity during the activa- 
tion. These results will be reported in a following 
communication. 
F ig. lA shows the cleavage pattern observed by 
SDS-PAGE during activation of PgA3. Concen- 
tration of polyacrylamide and degree of crosslink- 
ing were chosen for maximum resolution among 
pepsinogen, intermediates and pepsin: the actual 
distance between the bands of pepsinogen and pep- 
sin was 10 mm. The liberated peptides were not 
observed under these conditions. An intermediate 
is observed from 0.5 to 6 min, and the conversion 
into pepsin is completed after 15 min of activation. 
In a preparative experiment, 100/~g PgA3 
(2.5 nmol) was activated for 2 min; after elec- 
trophoresis the zones were electroblotted on Im- 
mobilon, and sequenced with the results shown in 
fig.2. The sequence of the intermediate shows that 
cleavage has occurred between Leu-23 and Lys-24. 
In all investigations on the specificity of pepsin 
A, a preference for apolar side chains at binding 
site S'  1 is reported, e.g. [16]. Cleavage in front of 
Lys has never been found as a major cleavage site. 
In the present case other subsite bindings may be 
important, and the side chain of Lys may fold with 
the alkaline part (C~ to C6) to fit the apolar S ' I  
binding site, and with the e-amino group outside 
the substrate binding cleft. Future model building 
may solve the question. 
Sequencing of the intermediate was continued 
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Fig.1. Activation of human isopepsinogens analysed by SDS- 
PAGE. (A) Pepsinogen A3; (B) pepsinogen A5. Duration of 
activation indicated above the lanes. Upper bands, pepsinogen; 
middle, intermediate; lower, pepsin. Samples equivalent to 8 Ltg 
of pepsinogen were applied to each slit, pepsin has a lower 
colour value than that of pepsinogen. 
for 30 steps. At step no.20, corresponding to 
residue no.43 in human pepsinogen, Glu was seen 
without any trace of Lys. Thus, the propart of 
PgA3 corresponds to the N-terminal amino acid 
sequence reported by Sogawa et al. [6]. 
The conversion of PgA5 to pepsin takes place at 
a much slower rate than that of PgA3. In the ex- 
periment shown in fig. 1B, the zone of pepsinogen 
persists for 1.5 h, and a faint zone of intermediate 
appears after 30 min. A preparative activation was 
carried out with 100/~g of PgA5 for 45 min. The 
zones were electroblotted and sequenced. The 
results are summarized in fig.2. The intermediate 
zone produced a double sequence, indicating 
cleavage in front of Lys-24 and Phe-26. The two 
sequences occurred in the ratio 2 : 1, and were iden- 
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Fig.2. N-terminal amino acid sequences of human 
isopepsinogens. PgA3 sequence according to Sogawa et al. [6]. 
PgA5 sequence according to Evers et al. [7]. (AM Dig.) 
Sequences after digestion with Armillaria mellea proteinase. 
The horizontal arrows indicate sequences determined in the 
present investigations. Vertical arrows indicate cleavage points 
during the activation. The amino-terminus of pepsin is Val 
(underlined). 
tiffed through 5 steps (Lys-28 and His-30, respec- 
tively). Preparative activation of PgA5 was 
repeated with electrophoresis, electroblotting and 
sequencing after 2 h of activation. In this case the 
sequences starting with Lys-24 and Phe-26 occur- 
red in the ratio 1 : 10. 
In order to investigate if PgA5 has Lys at posi- 
tion no.43 the zymogen was digested with Ar- 
millaria mellea proteinase which cleaves in front of 
Lys with a high degree of specificity [12]. A 
precipitate which remained after 5 h of digestion 
was analysed by sequencing. A double sequence 
appeared, but through 6 steps it was easy to iden- 
tify the N-terminal sequence of pepsinogen 
together with a sequence starting with Lys and con- 
tinuing to the second residue in pepsin (Val). Thus, 
though the reaction was incomplete the results 
show that PgA5 has Lys at position 43 as found in 
[7], and the present investigations support previous 
preliminary results [3]. 
By amino acid sequencing of human pepsinogen 
Kageyama and Takahashi [10] found mostly the 
same sequence as that deduced from nucleotide se- 
quencing, but Arg-Lys at position 42-43. Their ac- 
tivation experiments were stopped by addition of 
pepstatin, and cleavage of the bond Asp- 
25-Phe-26 was observed. 
Electrostatic interactions are important for 
stabilizing the tertiary structure of pepsinogen [9]. 
Substitutions of basic residues may therefore in- 
fluence the conformational changes which make 
the peptide bonds available for cleavage. But in ad- 
dition to the substitutions in the propart of human 
PgA mentioned here, changes may also occur in 
the enzyme moiety of the zymogens. The 
nucleotide sequencings are carried out with DNA 
from embryonic [6] and placental [7] libraries. 
Such genes do not necessarily correspond to those 
that are dominantly expressed in the gastric 
mucosa. Amino acid analyses of the chromatog- 
raphically purified PgA3 and PgA5 show minor 
differences from the nucleotide derived composi- 
tions. The problem is under further investigation 
with fingerprint analyses. 
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NOTE ADDED IN PROOF 
The substitution of Glu to Lys in PgA3 and 
PgA5 was recently reported in another paper: 
Bank, R.A., Crusius, B.C., Zwiers, T., 
Meuwissen, S.G.M., Arwert, F. and Pronk, J.C. 
(1988) FEBS Lett. 238, 105-108. 
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